Aster DM Quality Care Ltd (ASTERDM) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 31, 2026 3 min read

Aster DM Quality Care Ltd enters its first quarter as a merged entity, following the formal integration of Quality Care India Ltd on July 1, 2026. Investors are looking to the Q1 results to gauge the initial impact of recent greenfield hospital commissioning and the sustainability of high-margin specialty growth.

Quick Details

Results date	August 05, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 1,182 Cr
Previous quarter PAT	Rs. 140 Cr
Previous quarter EBITDA margin	20.7%
Market cap	Rs. 71,646.95 Cr
CMP	Rs. 822.15

Aster DM Quality Care Ltd Q1 Results Date and Time

The board meeting is scheduled for August 05, 2026, to consider the audited financial results.

What to expect from Aster DM Quality Care Ltd's Q1 FY27 results

Management's forward-looking thesis centers on sustaining double-digit volume growth following the flat performance seen in Q1 FY26, with seasonal tailwinds from vector-borne disease hospitalizations providing a structural floor for occupancy. The commissioning of 634 new beds in April 2026 across Ramesh Ongole, Whitefield Block D, and Capital Trivandrum represents a significant expansion, though these units are expected to carry initial ramp-up losses during the quarter. The company continues to prioritize its CONGO-T specialty mix, which reached 58.7% in FY26, alongside a robust Cash & Insurance payor mix that hit 83% in the previous quarter. With the merger effective July 1, 2026, the upcoming call will focus on the first month of combined operations and the early realization of synergy potential from procurement and supply chain optimization. Management has guided for annual maintenance capex at 5% of revenue, and investors will monitor if the recent credit rating upgrades to AA+/Stable provide a meaningful reduction in financing costs for the ongoing expansion pipeline.

Key Things To Watch

Performance vs Guidance Tracking

Revenue growth — 16-17% in FY26 — 12% actual (standalone)
ARPP IP growth — 7-8% over 2-3 years — 9% actual in Q4 FY26
Bed additions — 878 in FY27 (merged) — 234 beds operationalized in April 2026

Greenfield Ramp-up Status

Capital Trivandrum (454 beds), Ramesh Ongole (75 beds), and Whitefield Block D (159 beds) operationalized in April 2026
Monitor pre-operative losses and timeline to breakeven relative to Nagercoil benchmark of 28.5% EBITDA margin within six quarters

Merger Integration and Synergies

First quarter including QCIL operations (effective July 1, 2026)
Targeting EBITDA upside of 10-15% of FY24 pro-forma EBITDA from procurement and supply chain optimization

Operating Metric Trajectory

Volume recovery: Q1 FY26 saw flat IP growth; monitoring for return to double-digit growth
CONGO-T mix: Target of 60-65% (58.7% achieved in FY26)
MVT sustainability: 41% YoY growth in Q4 FY26

Frequently Asked Questions

What is the status of the merger with Quality Care India Ltd?

The merger was approved by NCLT on June 19, 2026, and became effective on July 1, 2026. The combined entity, now named Aster DM Quality Care Ltd, operates 39 hospitals with over 10,600 beds.

How did Aster's standalone India business perform in its most recent quarter?

In Q4 FY26, the standalone India business reported revenue of Rs. 1,182 Cr, representing 18% YoY growth. Operating EBITDA reached Rs. 244 Cr with a margin of 20.7%.

Is the company on track with its ARPP IP growth guidance?

The company targeted ARPP IP growth of 7-8% over 2-3 years, and Q4 FY26 actual growth was 9% YoY. Management continues to focus on this metric as a key indicator of clinical complexity.